Published online Jul 6, 2015. doi: 10.5527/wjn.v4.i3.324
Peer-review started: January 26, 2015
First decision: March 6, 2015
Revised: March 19, 2015
Accepted: April 16, 2015
Article in press: April 20, 2015
Published online: July 6, 2015
Evidence is accumulating indicating a role for uric acid in the genesis and progression of kidney disease, and a few studies are beginning to show a possible beneficial effect of urate-lowering therapy. Whether this holds true for renal allograft recipients is not clear. In this short review evidence from epidemiological as well as intervention studies is summarized and discussed, with some practical considerations presented at the end.
Core tip: Hyperuricemia is a common finding following renal transplantation; its clinical, as well as prognostic, significance, however, is not known. We have summarized available evidence from human epidemiological and intervention studies and concluded that, in the absence of gout, evidence in support of treatment for this condition in renal graft recipients is insufficient at present, although, when required, treatment with low-dose allopurinol or febuxostat appears to be safe.